Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques.
BACKGROUND
Immature dendritic cells (DC) can promote long-term transplant survival in rodents. We assessed the impact of stably immature, donor-derived DC on alloimmune reactivity in rhesus macaques.


METHODS
CD14 monocytes isolated from leukapheresis products of Macacca mulatta were cultured in granulocyte-macrophage colony stimulating factor plus interleukin (IL)-4+/-vitamin (vit) D3, and IL-10. Major histocompatibility complex class II and cosignaling molecule expression was determined on CD11c cells by flow cytometry. T-cell allostimulatory capacity of the DC, including DC exposed to proinflammatory cytokines, was determined in mixed leukocyte reaction. To test their influence in vivo, purified DC were infused intravenously into allogeneic recipients, either alone or followed by CTLA4Ig, 24 hr later. Proliferative responses of recipient CFSE-labeled T cells to donor or third party DC, cytokine production by stimulated T cells, and circulating alloantibody levels were determined by flow cytometry, up to 100 days postinfusion.


RESULTS
VitD3/IL-10-conditioned, monocyte-derived DC were resistant to maturation and failed to induce allogeneic T cell proliferation in vitro. After their infusion, an increase in anti-donor and anti-third party T-cell reactivity was observed, that subsequently subsided to fall significantly below pretreatment levels (by day 56) only in animals also given CTLA4Ig. No increase in circulating immunoglobulin (Ig) M or IgG anti-donor alloantibody titers compared with pretreatment values was detected. With DC+CTLA4Ig infusion, alloreactive IL-10-producing T cells were prevalent in the circulation after day 28.


CONCLUSIONS
Maturation-resistant rhesus DC infusion is well-tolerated. DC+CTLA4Ig infusion modulates allogeneic T-cell responses and results in hyporesponsiveness to donor and third party alloantigens.
Zahorchak
Alan F
AF
Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Kean
Leslie S
LS
Tokita
Daisuke
D
Turnquist
Heth R
HR
Abe
Masanori
M
Finke
Jennifer
J
Hamby
Kelly
K
Rigby
Mark R
MR
Larsen
Christian P
CP
Thomson
Angus W
AW
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology*; D017690:Cell Transplantation / Q000379:methods*; D002478:Cells, Cultured; D002762:Cholecalciferol / Q000494:pharmacology; D017077:Culture Media, Conditioned; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D004195:Disease Models, Animal; D005434:Flow Cytometry; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D007075:Immunoglobulin M / Q000276:immunology; D016753:Interleukin-10 / Q000494:pharmacology; D007937:Leukapheresis; D018950:Lipopolysaccharide Receptors / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D008253:Macaca mulatta; D008264:Macrophages / Q000276:immunology; D010641:Phenotype; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D014184:Transplantation, Homologous
D000888:Antibodies, Anti-Idiotypic; D017077:Culture Media, Conditioned; D007075:Immunoglobulin M; D018950:Lipopolysaccharide Receptors; D016753:Interleukin-10; D002762:Cholecalciferol